1TYTGAT G N.Medical therapy of gastroesophageal reflux disease[A].In:Orlando R C.Gastroesophageal reflux disease[M].New York:Marcel Dekker Ine,2000.283-309.
2THJODLEIFSSON B,BEKER J A,DEKKERS C,et al.Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease:a double-blind,multicenter,European trial.The European Rabeprazole Study Group[J].Dig Dis Sci,2000,45(5)
3EDWARDS S J,LIND T,LUNDELL L.Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis[J].Aliment Pharmacol Ther,2001,15(11):1729-1736.
5Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus on the management of Helicobacterpylori infection. J Gastroenterol Hepatol, 1998,13: 1～12.
6European Helicobacter pylori Study Group. Current European concepts in the management ofHelicobacter pylori infection. The Maastricht Consensus Report. Gut, 1997, 41: 8～13.
7Miwa H, Ohkura R, Murai T, Sato K, NagaharaA, Hirai S, Watanabe S, Sato N. Impact of Rabeprazole, a new proton pump inhibitor, in tripletherapy of Helicobacter pylori infection-comparison with omeprazole and lansoprazole. AlimentPharmacol Ther, 1999, 13: 741～746.
8Lind T, Veldhuyzen van Zanten S, Unge P, SpillerR, Bayerdorffer E, O'Morain C, Bardhan KD, Bradette M, Chiba N, Wrangstadh M, Cederberg C,Idstrom JP. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study.Helicobacter, 1996, 1: 138～144.
9Besancon M, Simon A, Sachs G, Shin JM. Sites ofreaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J Biol Chem, 1997,272: 22438～22446.
10Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Comparison[correction of Double-blind, Placebo-Controlledcomparison] of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active gastric ulcer- a European multicentre study. The European Rabeprazole Study Group. Aliment Pharmacol Ther,1998, 12: 789～795.
3TYTGAT C N J.Shortcomings of the first generation proton pumpinhibitors[J].Eur J Gastorenterol Hapatol,2001,13 (1):29-32.
4WILLIAMS M P,POUNDER R E.Reviewarticle:the pharmacology of rabeprazole[J].Aliment Pharmacol Ther,1999,13(3):3-6.
5ISHIZAKI T.Cytochrome p450 and the metabolisn of proton pum pinhibitors-em phasis on rabeprazole[J].Aliment Phar macol Ther,1999,13 (3):27-29.
6SWANSK H,HOYUMMPA A M,MERRITT G J.Review article:the pharmacokinetics of rabeiprzile in health and disase[J].Aliment Pharmacol Ther,1999,13 (Suppl3):11-14.
7KOEK GH,TACK J,SIFRIM D,et al.Therole of acid and duodenal gastroesophageal refluxin symptomatic GERD[J].Am Gastroenterof,2001,96:2033.
8CORON E,HATLEBAKK IG,GALMICHE IP.Medicaltherapy of ga5troeso Phageal reflux disease[J].Curropin Gastroenterol,2007,23:434.
